DE60307616D1 - Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen - Google Patents

Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen

Info

Publication number
DE60307616D1
DE60307616D1 DE60307616T DE60307616T DE60307616D1 DE 60307616 D1 DE60307616 D1 DE 60307616D1 DE 60307616 T DE60307616 T DE 60307616T DE 60307616 T DE60307616 T DE 60307616T DE 60307616 D1 DE60307616 D1 DE 60307616D1
Authority
DE
Germany
Prior art keywords
imidazols
triazols
carbide
bonded
farnesyl transferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60307616T
Other languages
English (en)
Other versions
DE60307616T2 (de
Inventor
Janssen-Cilag Angibaud
Gaston Venet
Janssen-Cilag Argoullon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE60307616D1 publication Critical patent/DE60307616D1/de
Publication of DE60307616T2 publication Critical patent/DE60307616T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60307616T 2002-04-15 2003-04-14 Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen Expired - Lifetime DE60307616T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02076448 2002-04-15
EP02076448 2002-04-15
PCT/EP2003/003986 WO2003087101A1 (en) 2002-04-15 2003-04-14 Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles

Publications (2)

Publication Number Publication Date
DE60307616D1 true DE60307616D1 (de) 2006-09-28
DE60307616T2 DE60307616T2 (de) 2007-10-04

Family

ID=29225666

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60307616T Expired - Lifetime DE60307616T2 (de) 2002-04-15 2003-04-14 Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen

Country Status (9)

Country Link
US (2) US7511138B2 (de)
EP (1) EP1497295B1 (de)
JP (1) JP4384505B2 (de)
AT (1) ATE336496T1 (de)
AU (1) AU2003229688B2 (de)
CA (1) CA2481480C (de)
DE (1) DE60307616T2 (de)
ES (1) ES2271574T3 (de)
WO (1) WO2003087101A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026263B2 (en) 2000-01-06 2011-09-27 The Regents Of The University Of California Methods for inhibiting neoproliferative changes in blood vessel walls

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
CA2231105C (en) 1995-12-08 2005-09-13 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
ATE366250T1 (de) 1997-04-25 2007-07-15 Janssen Pharmaceutica Nv Chinazolinone die farnesyltransferase hemmen
PT988038E (pt) 1997-06-02 2002-12-31 Janssen Pharmaceutica Nv Derivados (imidazol-5-il)metil-2-quinolinona como inibidores da proliferacao de celulas dos musculos lisos
EE04579B1 (et) 1998-07-06 2006-02-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
DK1094839T3 (da) 1998-07-06 2003-08-18 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhibitorer med in vivo radiosensibiliserende egenskaber
BR9913315A (pt) 1998-08-27 2001-05-22 Pfizer Prod Inc Derivados de quinolin-2-ona úteis como agentes anticâncer
AU4925499A (en) 1998-08-27 2000-03-21 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
WO2000039082A2 (en) * 1998-12-23 2000-07-06 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives
CN1340051A (zh) 1999-02-11 2002-03-13 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
DE10046993A1 (de) 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
JP4974438B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体
US7053105B2 (en) 2000-09-25 2006-05-30 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
WO2002024683A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体

Also Published As

Publication number Publication date
US7511138B2 (en) 2009-03-31
ATE336496T1 (de) 2006-09-15
WO2003087101A1 (en) 2003-10-23
US7655654B2 (en) 2010-02-02
CA2481480A1 (en) 2003-10-23
JP2005526109A (ja) 2005-09-02
US20050148609A1 (en) 2005-07-07
AU2003229688B2 (en) 2009-07-30
EP1497295A1 (de) 2005-01-19
AU2003229688A1 (en) 2003-10-27
CA2481480C (en) 2011-04-12
ES2271574T3 (es) 2007-04-16
DE60307616T2 (de) 2007-10-04
JP4384505B2 (ja) 2009-12-16
EP1497295B1 (de) 2006-08-16
US20080027086A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
DE60118225D1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
HK1078473A1 (en) Inhibitors of histone deacetylase
PL371100A1 (en) Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
PL370982A1 (en) Carbonylamino-derivatives as novel inhibitors of histone deacetylase
PL371036A1 (en) Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
TW200612920A (en) Novel imidazolidine derivatives
WO2002024686A3 (en) Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
PL370990A1 (en) Sulfonyl-derivatives as novel inhibitors of histone deacetylase
ES2121441T3 (es) Nuevos derivados de 3,5 -dioxo - (2h,4h) - 1,2,4 - triazina,su preparacion y aplicacion como farmaco
DE60214591D1 (en) Pyrazolpyrimidinfungizide
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
TW200720249A (en) Pyrrolidine compound
DE60117847D1 (de) Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
UA91002C2 (ru) 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
TW200616998A (en) Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
SE0302139D0 (sv) Novel compounds
IL159554A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
TW200508274A (en) Antioxidant and bisaminophenol derivative
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
DE60119383D1 (de) Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
SE9904128D0 (sv) Novel compounds
DE60307616D1 (de) Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
HUP0401885A2 (hu) Új hidroxialkil-indolokarbazol-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények
ES8702380A1 (es) Procedimiento para preparar un derivado de (imina ciclica)- difenil-eter

Legal Events

Date Code Title Description
8364 No opposition during term of opposition